We aim to investigate the potential roles of key genes in the development of lupus nephritis (LN), screen key biomarkers, and construct the lncRNA XIST/miR-381-3P/STAT1 axis by using bioinformatic prediction combined with clinical validation, thereby providing new targets and insights for clinical research.
Methods
Gene expression microarrays GSE157293 and GSE112943 were downloaded from the GEO database to obtain differentially expressed genes (DEGs), followed by enrichment analyses on these DEGs, which were enriched and analyzed to construct a protein-protein interaction (PPI) network to screen core genes. The lncRNA-miRNA-mRNA regulatory network was predicted and constructed based on the miRNA database. 37 female patients with systemic lupus erythematosus (SLE) were recruited to validate the bioinformatics results by exploring the diagnostic value of the target ceRNA axis in LN by dual luciferase and real-time fluorescence quantitative PCR (RT-qPCR) and receiver operating characteristic (ROC).
Results
The data represented that a total of 133 differential genes were screened in the GSE157293 dataset and 2869 differential genes in the GSE112943 dataset, yielding a total of 26 differentially co-expressed genes. Six core genes (STAT1, OAS2, OAS3, IFI44, DDX60, and IFI44L) were screened. Biological functional analysis identified key relevant pathways in LN. ROC curve analysis suggested that lncRNA XIST, miR-381-3P, and STAT1 could be used as potential molecular markers to assist in the diagnosis of LN.
Conclusion
STAT1 is a key gene in the development of LN. In conclusion, lncRNA XIST, miR-381-3P, and STAT1 can be used as new molecular markers to assist in the diagnosis of LN, and the lncRNA XIST/miR-381-3P/STAT1 axis may be a potential therapeutic target for LN.
TonsawanPSawanyawisuthK. Clinical comparisons between previously diagnosed SLE and newly diagnosed SLE by kidney biopsy. Auto Immun Highlights2020; 11: 18. DOI: 10.1186/s13317-020-00140-2.
3.
ParikhSVAlmaaniSBrodskyS, et al.Update on lupus nephritis: core curriculum 2020. Am J Kidney Dis2020; 76: 265–281. DOI: 10.1053/j.ajkd.2019.10.017.
4.
ShresthaSBudhathokiPAdhikariY, et al.Belimumab in lupus nephritis: a systematic review and meta-analysis. Cureus2021; 13: e20440. DOI: 10.7759/cureus.20440.
MiaoNWangZWangQ, et al.Oxidized mitochondrial DNA induces gasdermin D oligomerization in systemic lupus erythematosus. Nat Commun2023; 14: 872. DOI: 10.1038/s41467-023-36522-z.
8.
HeSDingHChenL, et al.Repression of interferon regulatory factor-4 (IRF4) hyperactivation restricts murine lupus. Signal Transduct Targeted Ther2023; 8: 188. DOI: 10.1038/s41392-023-01413-8.
9.
BrownGJCañetePFWangH, et al.TLR7 gain-of-function genetic variation causes human lupus. Nature2022; 605: 349–356. DOI: 10.1038/s41586-022-04642-z.
10.
DengYZhengYLiD, et al.Expression characteristics of interferon-stimulated genes and possible regulatory mechanisms in lupus patients using transcriptomics analyses. EBioMedicine2021; 70: 103477. DOI: 10.1016/j.ebiom.2021.103477.
11.
WangYJiaWMaQ, et al.Identification of IFI44L as a new candidate molecular marker for systemic lupus erythematosus. Clin Exp Rheumatol2023; 41: 48–59. DOI: 10.55563/clinexprheumatol/q3aa6s.
12.
WangYMaCMaZ, et al.Identification and clinical correlation analysis of IFI44 in systemic lupus erythematosus combined with bioinformatics and immune infiltration analysis. J Inflamm Res2023; 16: 3219–3231. DOI: 10.2147/jir.S419880.
13.
ShenMDuanCXieC, et al.Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus. Front Immunol2022; 13: 962393. DOI: 10.3389/fimmu.2022.962393.
14.
CaoYTangWTangW. Immune cell infiltration characteristics and related core genes in lupus nephritis: results from bioinformatic analysis. BMC Immunol2019; 20: 37. DOI: 10.1186/s12865-019-0316-x.
15.
ChenZLanRYeK, et al.Prioritization of diagnostic and prognostic biomarkers for lupus nephritis based on integrated bioinformatics analyses. Front Bioeng Biotechnol2021; 9: 717234. DOI: 10.3389/fbioe.2021.717234.
16.
WangZHuDPeiG, et al.Identification of driver genes in lupus nephritis based on comprehensive bioinformatics and machine learning. Front Immunol2023; 14: 1288699. DOI: 10.3389/fimmu.2023.1288699.
17.
PhilipsRLWangYCheonH, et al.The JAK-STAT pathway at 30: much learned, much more to do. Cell2022; 185: 3857–3876. DOI: 10.1016/j.cell.2022.09.023.
18.
HadjadjJCastroCNTusseauM, et al.Early-onset autoimmunity associated with SOCS1 haploinsufficiency. Nat Commun2020; 11: 5341. DOI: 10.1038/s41467-020-18925-4.
19.
MeyerLKVerbistKCAlbeituniS, et al.JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood2020; 136: 657–668. DOI: 10.1182/blood.2020006075.
20.
PomaznoyMHaBPetersB. GOnet: a tool for interactive gene ontology analysis. BMC Bioinf2018; 19: 470. DOI: 10.1186/s12859-018-2533-3.
21.
KanehisaMFurumichiMTanabeM, et al.KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res2017; 45: D353–D361. DOI: 10.1093/nar/gkw1092.
22.
ItoKMurphyD. Application of ggplot2 to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol2013; 2: e79. DOI: 10.1038/psp.2013.56.
23.
SzklarczykDKirschRKoutrouliM, et al.The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res2023; 51: D638–d646. DOI: 10.1093/nar/gkac1000.
24.
AringerMCostenbaderKDaikhD, et al.2019 European league against rheumatism/American college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol2019; 71: 1400-1412. DOI: 10.1002/art.40930.
25.
RobinXTurckNHainardA, et al.pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinf2011; 12: 77. DOI: 10.1186/1471-2105-12-77.
26.
YuCLiPDangX, et al.Lupus nephritis: new progress in diagnosis and treatment. J Autoimmun2022; 132: 102871. DOI: 10.1016/j.jaut.2022.102871.
27.
AringerMLeuchtenNDörnerT. Biologicals and small molecules for systemic lupus erythematosus. Z Rheumatol2020; 79: 232–240. DOI: 10.1007/s00393-020-00767-6.
28.
ZhangQLiangYYuanH, et al.Integrated analysis of lncRNA, miRNA and mRNA expression profiling in patients with systemic lupus erythematosus. Arch Med Sci2019; 15: 872–879. DOI: 10.5114/aoms.2018.79145.
29.
XuanJXiongYShiL, et al.Do lncRNAs and circRNAs expression profiles influence discoid lupus erythematosus progression? a comprehensive analysis. Ann Transl Med2019; 7: 728. DOI: 10.21037/atm.2019.12.10.
30.
ZhangLWuHZhaoM, et al.Identifying the differentially expressed microRNAs in autoimmunity: a systemic review and meta-analysis. Autoimmunity2020; 53: 122–136. DOI: 10.1080/08916934.2019.1710135.
31.
DerESuryawanshiHMorozovP, et al.Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol2019; 20: 915–927. DOI: 10.1038/s41590-019-0386-1.
32.
DingXRenYHeX. IFN-I mediates lupus nephritis from the beginning to renal fibrosis. Front Immunol2021; 12: 676082. DOI: 10.3389/fimmu.2021.676082.
33.
IwamotoTDorschnerJMSelvarajS, et al.High systemic type I interferon activity is associated with active class III/IV lupus nephritis. J Rheumatol2022; 49: 388–397. DOI: 10.3899/jrheum.210391.
34.
Ugolini-LopesMRTorrezanGTGândaraAPR, et al.Enhanced type I interferon gene signature in primary antiphospholipid syndrome: association with earlier disease onset and preeclampsia. Autoimmun Rev2019; 18: 393–398. DOI: 10.1016/j.autrev.2018.11.004.
35.
CrowMKOlferievMKirouKA. Type I interferons in autoimmune disease. Annu Rev Pathol2019; 14: 369–393. DOI: 10.1146/annurev-pathol-020117-043952.
36.
GallucciSMekaSGameroAM. Abnormalities of the type I interferon signaling pathway in lupus autoimmunity. Cytokine2021; 146: 155633. DOI: 10.1016/j.cyto.2021.155633.
37.
IvashkivLBDonlinLT. Regulation of type I interferon responses. Nat Rev Immunol2014; 14: 36–49. DOI: 10.1038/nri3581.
38.
BaechlerECBatliwallaFMKarypisG, et al.Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A2003; 100: 2610–2615. DOI: 10.1073/pnas.0337679100.
39.
LiangYXuWDYangXK, et al.Association of signaling transducers and activators of transcription 1 and systemic lupus erythematosus. Autoimmunity2014; 47: 141–145. DOI: 10.3109/08916934.2013.873415.
40.
CaiZZhangSWuP, et al.A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis. Clin Transl Med2021; 11: e309. DOI: 10.1002/ctm2.309.
41.
WallaceDJFurieRATanakaY, et al.Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet2018; 392: 222-231. DOI: 10.1016/s0140-6736(18)31363-1.
42.
DörnerTTanakaYDowER, et al.Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis2022; 81: 1267–1272. DOI: 10.1136/annrheumdis-2022-222335.
43.
LeeJParkYJangSG, et al.Baricitinib attenuates autoimmune phenotype and podocyte injury in a murine model of systemic lupus erythematosus. Front Immunol2021; 12: 704526. DOI: 10.3389/fimmu.2021.704526.
44.
O'SheaJJSchwartzDMVillarinoAV, et al.The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med2015; 66: 311–328. DOI: 10.1146/annurev-med-051113-024537.
45.
XinPXuXDengC, et al.The role of JAK/STAT signaling pathway and its inhibitors in diseases. Int Immunopharm2020; 80: 106210. DOI: 10.1016/j.intimp.2020.106210.
46.
Au-YeungNMandhanaRHorvathCM. Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway. JAK-STAT2013; 2: e23931. DOI: 10.4161/jkst.23931.
47.
ChengCZhuRLiuM, et al.Kunxian capsule alleviates renal damage by inhibiting the JAK1/STAT1 pathway in lupus nephritis. J Ethnopharmacol2023; 310: 116349. DOI: 10.1016/j.jep.2023.116349.
48.
ShiDLiYShiX, et al.Transcriptional expression of CXCL10 and STAT1 in lupus nephritis and the intervention effect of triptolide. Clin Rheumatol2023; 42: 539–548. DOI: 10.1007/s10067-022-06400-y.
49.
SyrettCMSindhavaVHodawadekarS, et al.Loss of Xist RNA from the inactive X during B cell development is restored in a dynamic YY1-dependent two-step process in activated B cells. PLoS Genet2017; 13: e1007050. DOI: 10.1371/journal.pgen.1007050.
50.
SyrettCMSierraIBeethemZT, et al.Loss of epigenetic modifications on the inactive X chromosome and sex-biased gene expression profiles in B cells from NZB/W F1 mice with lupus-like disease. J Autoimmun2020; 107: 102357. DOI: 10.1016/j.jaut.2019.102357.
51.
LongBWanYZhangS, et al.LncRNA XIST protects podocyte from high glucose-induced cell injury in diabetic nephropathy by sponging miR-30 and regulating AVEN expression. Arch Physiol Biochem2023; 129: 610–617. DOI: 10.1080/13813455.2020.1854307.
52.
CaiYChenSJiangX, et al.LncRNA X inactive specific transcript exerts a protective effect on high glucose-induced podocytes by promoting the podocyte autophagy via miR-30d-5p/BECN-1 Axis. Internet J Endocrinol2023; 2023: 3187846. DOI: 10.1155/2023/3187846.
53.
JinLWPanMYeHY, et al.Down-regulation of the long non-coding RNA XIST ameliorates podocyte apoptosis in membranous nephropathy via the miR-217-TLR4 pathway. Exp Physiol2019; 104: 220–230. DOI: 10.1113/ep087190.
54.
RipollÈde RamonLDraibe BordignonJ, et al.JAK3-STAT pathway blocking benefits in experimental lupus nephritis. Arthritis Res Ther2016; 18: 134. DOI: 10.1186/s13075-016-1034-x.
55.
Martinez-LostaoLOrdi-RosJBaladaE, et al.Activation of the signal transducer and activator of transcription-1 in diffuse proliferative lupus nephritis. Lupus2007; 16: 483–488. DOI: 10.1177/0961203307079618.
56.
XiaoZXHuXZhangX, et al.High salt diet accelerates the progression of murine lupus through dendritic cells via the p38 MAPK and STAT1 signaling pathways. Signal Transduct Targeted Ther2020; 5: 34. DOI: 10.1038/s41392-020-0139-5.
